Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00803049 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 742
- Enrollment target
NCT00803049 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 742 participants.
The verdict
NCT00803049, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 742 participants
- Enrollment target
Study Summary
The primary objective of this study was to document the long-term safety and tolerability of teriflunomide in Multiple Sclerosis (MS) participants with relapse. The secondary objective was to document the long-term efficacy on disability progression, relapse rate and Magnetic Resonance Imaging (MRI) parameters.
Interventions
- DRUG Teriflunomide (HMR1726)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 742 participants |
| Start Date | 2006-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00803049
The ClinicalTrials.gov registry entry for NCT00803049 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 742 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Teriflunomide (HMR1726) is the first listed.
NCT00803049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00803049 about?
NCT00803049 is a clinical study titled "Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis". The primary objective of this study was to document the long-term safety and tolerability of teriflunomide in Multiple Sclerosis (MS) participants with relapse. The secondary objective was to document the long-term efficacy on disability progression, relapse rate and Magnetic Resonance Imaging (MRI...
What is the current status of trial NCT00803049?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 742 participants. The study started on 2006-10. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00803049?
The interventions under investigation include: Teriflunomide (HMR1726) (DRUG).
Who is sponsoring clinical trial NCT00803049?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.